Shaggy Bracket

Metadata

Regulatory Status

United States

• FDA GRAS Status: Not established. Inonotus hispidus has no history of use as a food ingredient in the United States and is not marketed as a dietary supplement.
• Dietary Supplement: Not marketed. No NDI notification has been filed with the FDA.

European Union

• Novel Food Status: Not authorized under Regulation (EU) 2015/2283. No history of consumption as food in Europe, though the species is widely distributed across the continent.
• EMA/HMPC: No monograph. Not within the scope of European phytotherapy.
• Traditional use: Some historical recognition in European folk mycology for its conspicuous appearance on fruit trees, but no established medicinal tradition comparable to the Hymenochaetaceae species used in East Asian medicine.

China

• Not listed in the Chinese Pharmacopoeia. Unlike its relatives Sanghuangporus sanghuang and Phellinus linteus, I. hispidus does not have an established TCM identity, though some Chinese research groups have investigated its bioactive compounds.

Japan

• Not listed in the Japanese Pharmacopoeia. No established Kampo or folk medicine use.

Conditions & Indications

Primary Indications (Preclinical Evidence Only)

• Blood glucose regulation / anti-diabetic potential: Hispidin demonstrates potent alpha-glucosidase inhibitory activity in vitro, with IC50 values comparable to the pharmaceutical alpha-glucosidase inhibitor acarbose. Animal studies show that hispidin reduces postprandial blood glucose elevation in streptozotocin-induced diabetic mice through alpha-glucosidase inhibition and enhancement of AMPK (AMP-activated protein kinase) signaling in skeletal muscle and liver, promoting glucose uptake and glycogen synthesis. The alpha-glucosidase inhibition mechanism is shared with the pharmaceutical drug acarbose and the natural compound berberine, but hispidin combines this with AMPK activation for a dual-target anti-diabetic mechanism.
• Lipid metabolism modulation: I. hispidus extracts reduce total cholesterol, LDL cholesterol, and triglycerides in hyperlipidemic animal models while increasing HDL cholesterol. The mechanism involves hispidin-mediated activation of AMPK, which suppresses hepatic lipogenesis via inhibition of sterol regulatory element-binding protein-1c (SREBP-1c) and HMG-CoA reductase expression. These preclinical findings suggest potential cardiovascular and metabolic benefits, though no human data exists.

Secondary Indications (Preclinical Evidence Only)

• Antioxidant activity: Hispidin and related styrylpyrones demonstrate exceptionally strong antioxidant activity in multiple in vitro assays (DPPH, ABTS, FRAP, ORAC), exceeding the activity of reference antioxidants including ascorbic acid and BHT on a molar basis. The catechol moiety of hispidin’s structure enables both radical scavenging and metal chelation. I. hispidus fruiting body extracts protect against oxidative stress-induced cell damage in hepatocyte and neuronal cell culture models.
• Anti-inflammatory activity: Hispidin and hispolon suppress NF-kB signaling and reduce production of pro-inflammatory mediators (TNF-alpha, IL-6, IL-1beta, NO, PGE2) in lipopolysaccharide-stimulated macrophage models. Hispolon also inhibits COX-2 and iNOS expression. The anti-inflammatory mechanism parallels that of other Hymenochaetaceae phenolic compounds.

Emerging/Preclinical Indications

• Anti-tumor activity: Hispolon demonstrates anti-proliferative effects against multiple cancer cell lines (hepatocellular carcinoma, breast cancer, gastric cancer) through induction of apoptosis via mitochondrial pathway activation, cell cycle arrest at G2/M phase, and inhibition of NF-kB-mediated survival signaling. Hispolon also suppresses tumor angiogenesis in zebrafish and chick chorioallantoic membrane models. These findings are preliminary and no animal tumor models or human studies have been conducted with I. hispidus specifically.
• Hepatoprotective effects: I. hispidus polysaccharides and phenolic extracts demonstrate hepatoprotective activity in carbon tetrachloride-induced liver injury models in mice, reducing serum transaminase levels and histological liver damage. The mechanism involves antioxidant and anti-inflammatory activity.
• Immunomodulation: Beta-glucan polysaccharides from I. hispidus activate macrophages and enhance splenocyte proliferation through Dectin-1 signaling, consistent with the immunomodulatory activity common to medicinal mushroom polysaccharides. This activity has not been characterized as extensively as for the primary immunomodulatory mushrooms (turkey tail, reishi, maitake).

Mechanism of Action

Primary Mechanisms

1. Hispidin Styrylpyrone Antioxidant and Metabolic Activity Hispidin (6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone) is a styrylpyrone pigment first isolated from Inonotus hispidus and subsequently identified across multiple Hymenochaetaceae species including Phellinus linteus, Sanghuangporus sanghuang, and Inonotus obliquus (chaga). The compound’s catechol (ortho-dihydroxyphenyl) ring enables potent radical scavenging through hydrogen atom donation and semiquinone radical stabilization, while the adjacent hydroxyl groups chelate pro-oxidant transition metals (Fe2+, Cu2+). Hispidin activates the Nrf2/ARE antioxidant response pathway, upregulating endogenous antioxidant enzymes (SOD, CAT, GPx, HO-1). The metabolic effects are mediated through direct alpha-glucosidase inhibition (competitive binding at the active site) and AMPK activation in hepatocytes and skeletal muscle cells, which simultaneously promotes glucose uptake, suppresses hepatic gluconeogenesis, and inhibits lipogenesis.

2. Hispolon Anti-inflammatory and Anti-proliferative Activity Hispolon is a closely related styrylpyrone that inhibits NF-kB nuclear translocation by preventing IkB-alpha phosphorylation and degradation, suppressing the transcription of pro-inflammatory genes (COX-2, iNOS, TNF-alpha, IL-6). Hispolon also activates the intrinsic apoptotic pathway in cancer cell lines through mitochondrial membrane depolarization, cytochrome c release, and caspase-3/9 activation, with selectivity for transformed cells over normal cells in some in vitro models.

3. Polysaccharide Immunomodulation Inonotus hispidus fruiting body polysaccharides contain beta-1,3/1,6-glucan structures that activate innate immune cells through Dectin-1 and complement receptor 3 (CR3) signaling on macrophages and dendritic cells. This activity is consistent with the well-characterized immunomodulatory mechanism shared across medicinal mushrooms, though it has been less extensively studied in I. hispidus than in turkey tail, reishi, or maitake.

Secondary Mechanisms

4. Alpha-glucosidase Inhibition Hispidin competitively inhibits intestinal alpha-glucosidase enzymes, slowing the hydrolysis of dietary disaccharides and oligosaccharides to absorbable monosaccharides. This delays postprandial glucose absorption and reduces blood glucose spikes, a mechanism identical to the pharmaceutical drug acarbose. The IC50 values for hispidin are in the low micromolar range, comparable to acarbose.

5. AMPK Pathway Activation Hispidin activates AMPK through an LKB1-dependent mechanism, functioning as a metabolic master switch that simultaneously promotes catabolic pathways (fatty acid oxidation, glucose uptake) and suppresses anabolic pathways (lipogenesis, gluconeogenesis). This dual metabolic effect provides the mechanistic basis for both the anti-diabetic and lipid-lowering activities observed in preclinical models.

Taxonomic Pharmacology Note

Inonotus hispidus belongs to the family Hymenochaetaceae, which contains several of the most medicinally significant polypore genera: Inonotus (including I. obliquus / chaga), Phellinus (including P. linteus), and Sanghuangporus (including S. sanghuang). These species share a common styrylpyrone biosynthetic pathway producing hispidin and its derivatives, but differ in their total compound profiles, traditional uses, and evidence bases. Chaga is the best-known and most commercially available Hymenochaetaceae species in Western markets; I. hispidus shares its core styrylpyrone pharmacology but remains comparatively understudied. The species-specific compound ratios (hispidin:hispolon:inoscavins:phelligridins) differ across Hymenochaetaceae members, and these differences may have pharmacological significance that has not yet been fully characterized.

Clinical Evidence Summary

There are no published clinical trials evaluating Inonotus hispidus in human subjects. All evidence is preclinical (in vitro cell culture and in vivo animal models).

Preclinical Evidence

Evidence Limitations

• No clinical trials in human subjects have been published. All evidence derives from in vitro and animal studies, which cannot be directly extrapolated to human efficacy or dosing.
• Many pharmacological studies of hispidin use purified compound rather than whole I. hispidus extracts. The bioavailability of hispidin from crude fungal preparations in humans has not been established.
• The preclinical metabolic effects (alpha-glucosidase inhibition, AMPK activation, lipid-lowering) are promising but have not been validated in human metabolic disorder populations.
• Inonotus hispidus is much less studied than its Hymenochaetaceae relatives (chaga, P. linteus, S. sanghuang). Some pharmacological properties may be inferred from family-level data, but species-specific clinical validation is absent.
• Standardization of I. hispidus preparations (hispidin content, polysaccharide content) has not been established. Bioactive compound concentrations vary with host tree species, geographic origin, harvest timing, and extraction method.
• Publication bias toward positive preclinical results is a general concern in the medicinal mushroom literature.

Safety Profile

General Assessment

Inonotus hispidus has no established history of human medicinal use at scale, and safety data is derived entirely from preclinical toxicology studies and the general safety profile of edible/medicinal polypore fungi. The species is not known to produce any toxins and is not considered poisonous, though it is not traditionally consumed as food due to its tough, fibrous texture. No adverse events have been reported in the limited literature.

Contraindications

• Pregnancy and lactation: No safety data of any kind. Contraindicated by default.
• Known allergy to Hymenochaetaceae fungi: Individuals with known allergies to polypore fungi should avoid use.
• Pre-surgical: No data on anticoagulant or antiplatelet effects. Prudent to follow standard supplement discontinuation guidelines (2 weeks pre-surgery).

Drug Interactions

No drug interactions have been documented. Theoretical considerations based on preclinical pharmacology include:

• Antidiabetic medications (metformin, sulfonylureas, alpha-glucosidase inhibitors): Hispidin’s alpha-glucosidase inhibition and AMPK activation could theoretically produce additive hypoglycemic effects. No clinical interactions documented. Theoretical severity: Low.
• Lipid-lowering medications (statins): Hispidin’s AMPK-mediated suppression of HMG-CoA reductase expression parallels the statin mechanism. Additive lipid-lowering effects are theoretically possible. Theoretical severity: Low.
• Anticoagulants/antiplatelets: Some Hymenochaetaceae species demonstrate mild antiplatelet activity. Not specifically studied in I. hispidus. Theoretical severity: Low.

Overall, Inonotus hispidus is classified as having no documented drug interactions based on the absence of clinical data. Theoretical interactions are extrapolated from preclinical pharmacology.

Adverse Effects

• No human adverse effect data exists. The species is not widely consumed as a supplement or food.
• Preclinical toxicology studies in rodents have not revealed significant adverse effects at doses tested, but comprehensive toxicological characterization (subchronic, chronic, reproductive, genotoxicity) has not been completed.

Toxicology

• Limited toxicological data. No reports of acute toxicity in animal models at doses used in pharmacological studies.
• Inonotus hispidus is not classified as a toxic or poisonous fungus in mycological references.
• No evidence of hepatotoxicity in preclinical models; paradoxically, hepatoprotective effects have been demonstrated.
• Comprehensive toxicological evaluation (Ames test, chromosomal aberration, subchronic feeding studies) has not been published for I. hispidus specifically.

Clinical Dosage

No Established Human Dosage

There are no clinical trials establishing effective doses for Inonotus hispidus in humans. The following information is provided for reference based on preclinical research and extrapolation from related species.

Dried Fruiting Body Powder (Extrapolated)

• Estimated dose: 1-3 g/day of dried fruiting body powder, by analogy with dosing of other Hymenochaetaceae medicinal fungi (chaga, Phellinus linteus)
• Note: This is not a clinically validated dose. Hispidin content in crude fruiting body powder is highly variable.

Standardized Extract (Hypothetical)

• Preferred approach: An extract standardized to hispidin and/or total styrylpyrone content would be the preferred form for metabolic indications, given that hispidin is the primary bioactive for alpha-glucosidase inhibition and AMPK activation.
• Note: No standardized I. hispidus extracts are commercially available as of this writing.

Preclinical Dosing Reference

• Animal studies typically use hispidin at 10-50 mg/kg body weight in rodents or I. hispidus ethanol extracts at 100-500 mg/kg. Direct human dose translation from rodent models requires allometric scaling and pharmacokinetic validation, which has not been performed.

Product Quality Considerations

• Wild harvest: I. hispidus is collected from wild fruiting bodies on hardwood trees. There is no established commercial cultivation. Host tree species, geographic location, and harvest timing significantly influence bioactive compound concentrations.
• Identification: Correct species identification is critical. Inonotus hispidus can be confused with other Inonotus species, some of which may have different compound profiles. Confirmation by an experienced mycologist or DNA barcoding is advisable.
• Extract standardization: No standardization parameters are established for I. hispidus products. Hispidin content analysis by HPLC would be the most pharmacologically relevant quality parameter but is not routinely performed.
• Availability: I. hispidus is not widely available as a supplement. It may be encountered through specialized medicinal mushroom suppliers or through direct wild harvest.

Sources

• Lim HW, Lim HY, Wong KP. Uncovering the molecular mechanism of hispidin: alpha-glucosidase inhibitory activity and AMPK activation. J Agric Food Chem. 2014;62(32):8156-8163
• Huang SC, Kuo PC, Hung HY, et al. Hispidin protects against carbon tetrachloride hepatotoxicity through activation of AMPK and Nrf2 signaling. Toxicol Appl Pharmacol. 2012;264(3):358-367
• Jung JY, Lee IK, Seok SJ, Lee HJ, Kim YH, Yun BS. Antioxidant polyphenols from the mycelial culture of the medicinal fungi Inonotus xeranticus and Phellinus linteus. J Appl Microbiol. 2008;104(6):1824-1832
• Chen W, Feng L, Huang Z, Su H. Hispidin produced from Phellinus linteus protects against peroxynitrite-mediated DNA damage and hydroxyl radical generation. Chem Biol Interact. 2012;199(3):137-142
• Lu TL, Huang GJ, Wang HJ, et al. Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells. Food Chem Toxicol. 2009;47(8):2013-2021
• Kim JH, Lee JS, Hong SM, et al. Hepatoprotective effect of Inonotus hispidus polysaccharides against carbon tetrachloride-induced liver injury in mice. Int J Biol Macromol. 2016;82:537-543
• Ali NAA, Jansen R, Pilgrim H, Liberra K, Lindequist U. Hispidin, a yellow pigment from Inonotus hispidus. Phytochemistry. 1996;41(3):927-929
• Lee IK, Yun BS. Styrylpyrone-class compounds from medicinal fungi Phellinus and Inonotus spp., and their medicinal importance. J Antibiot (Tokyo). 2011;64(5):349-359
• Mo S, Wang S, Zhou G, et al. Phelligridins C-F, cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius. J Nat Prod. 2004;67(5):823-828
• Awadh Ali NA, Mothana RA, Lesnau A, Pilgrim H, Lindequist U. Antiviral activity of Inonotus hispidus. Fitoterapia. 2003;74(5):483-485
• Shao HJ, Jeong JB, Kim KJ, Lee SH. Anti-inflammatory activity of mushroom-derived hispidin through blocking of NF-kappaB activation. J Sci Food Agric. 2015;95(12):2482-2486

Connections

• Chaga — Chaga (Inonotus obliquus) is the best-known medicinal species in the genus Inonotus and shares the hispidin-producing styrylpyrone biosynthetic pathway with I. hispidus. Both species produce hispidin, but chaga is far better characterized pharmacologically and commercially, with a focus on antioxidant and immune-modulatory applications. Chaga grows on birch trees and accumulates birch-derived betulinic acid, which I. hispidus (growing on non-birch hardwoods) lacks. The two species represent different ecological and phytochemical strategies within the same genus.
• Sanghuangporus sanghuang — Another Hymenochaetaceae member with overlapping styrylpyrone chemistry. S. sanghuang has a much more extensive traditional medicine history in East Asia and stronger evidence for immune-modulatory and anti-tumor applications. Both species produce hispidin-class compounds, but S. sanghuang has been studied more extensively for its polysaccharide immunology.
• Meshima — Phellinus linteus (Meshima) is a closely related Hymenochaetaceae species that is one of the most extensively studied sources of hispidin and hispolon. Much of the pharmacological understanding of hispidin compounds has been generated through P. linteus research, and the findings are likely translatable to I. hispidus given the shared compound chemistry, though species-specific validation is needed.
• Inonotus hispidus fills a metabolic-support niche among the Hymenochaetaceae medicinal fungi, where its relatives chaga, Sanghuangporus, and Meshima are primarily positioned as immune-modulatory and antioxidant agents. The alpha-glucosidase inhibition and AMPK activation data, while preclinical, suggest a more specific metabolic pharmacology than the broadly antioxidant profile typically attributed to this fungal family.
• Synergy note: The combination of I. hispidus (hispidin-mediated metabolic support) with chaga (betulinic acid antioxidant + hispidin) would provide complementary Hymenochaetaceae styrylpyrone compounds from two different ecological sources, though this combination has not been studied and both species lack clinical trial validation for metabolic endpoints.